Cargando…

Effective Chemoimmunotherapy with Anti-TGFβ Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer

TGFβ is reportedly responsible for accumulation of CD4(+)Foxp3(+) regulatory T cells (Tregs) in tumor. Thus, we treated mouse 4T1 mammary carcinoma with 1D11, a neutralizing anti-TGFβ (1,2,3) antibody. The treatment delayed tumor growth, but unexpectedly increased the proportion of Tregs in tumor. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xin, Yang, Yuan, Zhou, Qiong, Weiss, Jonathan M., Howard, OlaMae Zack, McPherson, John M., Wakefield, Lalage M., Oppenheim, Joost J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887137/ https://www.ncbi.nlm.nih.gov/pubmed/24416401 http://dx.doi.org/10.1371/journal.pone.0085398

Ejemplares similares

Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
por: Chen, Xin, et al.
Publicado: (2014)

Quantitation of TGF-β proteins in mouse tissues shows reciprocal changes in TGF-β1 and TGF-β3 in normal vs neoplastic mammary epithelium
por: Flanders, Kathleen C., et al.
Publicado: (2016)

Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-β
por: Park, Hae-Young, et al.
Publicado: (2009)

Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide
por: Malvicini, Mariana, et al.
Publicado: (2012)

Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.
por: Eggermont, A. M., et al.
Publicado: (1988)

Transforming growth factor-β and breast cancer: Lessons learned from genetically altered mouse models
por: Wakefield, Lalage M, et al.
Publicado: (2000)

Dual-responsive nanosystem based on TGF-β blockade and immunogenic chemotherapy for effective chemoimmunotherapy
por: Huang, Xiaoxian, et al.
Publicado: (2022)

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes
Publicado: (1981)

Chemokines as Molecular Targets for Therapeutic Intervention
por: Howard, O. M. Zack, et al.
Publicado: (1999)

Transient Tumor-Fibroblast Interactions Increase Tumor Cell Malignancy by a TGF-β Mediated Mechanism in a Mouse Xenograft Model of Breast Cancer
por: Stuelten, Christina H., et al.
Publicado: (2010)

Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes
por: Colchester, Nancy T. H., et al.
Publicado: (2020)

Differential Proteome Analysis Identifies TGF-β-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model
por: Sato, Misako, et al.
Publicado: (2015)

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment
por: Xu, Xiaoli, et al.
Publicado: (2022)

Chemokine receptors on dendritic cells promote autoimmune reactions
por: Oppenheim, Joost J, et al.
Publicado: (2002)

Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
por: Zhong, Hui, et al.
Publicado: (2020)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
por: Hinchliffe, M., et al.
Publicado: (1983)

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
por: Stevenson, James P, et al.
Publicado: (2013)

Chemoimmunotherapy as long-term maintenance therapy for cancer
por: Egilmez, Nejat K., et al.
Publicado: (2012)

Complete response of metastatic gastric cancer to chemoimmunotherapy
por: Ina, Kenji, et al.
Publicado: (2017)

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
por: Wang, Tianqi, et al.
Publicado: (2021)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGFβ signaling in the mammary gland
por: Kohn, Ethan A, et al.
Publicado: (2010)

Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics
por: Chen, Jin-Qiu, et al.
Publicado: (2015)

Cancer cell progression and chemoimmunotherapy--dual effects in the induction of resistance to therapy.
por: Hamuro, J., et al.
Publicado: (1996)

Elimination of established tumors with nanodisc-based combination chemoimmunotherapy
por: Kuai, Rui, et al.
Publicado: (2018)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

Resistance to chemoimmunotherapy in non-small-cell lung cancer
por: Hochmair, Maximilian Johannes
Publicado: (2020)

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
por: Liu, Siyan, et al.
Publicado: (2022)

Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy
por: Lee, Yonghyun, et al.
Publicado: (2023)

Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy
por: Yu, Xinyang, et al.
Publicado: (2023)

Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles
por: Da Silva, Candido G., et al.
Publicado: (2019)

Delay Differential Model for Tumour-Immune Response with Chemoimmunotherapy and Optimal Control
por: Rihan, F. A., et al.
Publicado: (2014)

Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse.
por: Alberts, D. S., et al.
Publicado: (1978)

Proceedings: Lack of synergy between n-methyl-N-nitrosourea (MNU) and cyclophosphamide (CP) in rat urinary bladder.
por: Wakefield, J. S., et al.
Publicado: (1974)

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy
por: Shanavas, Mohamed, et al.
Publicado: (2021)

Supplementation of l‐arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy
por: Satoh, Yusuke, et al.
Publicado: (2020)

Recurrent spindle cell carcinoma of the lung successfully treated by chemoimmunotherapy
por: Akaba, Tomohiro, et al.
Publicado: (2021)

A dual-responsive doxorubicin–indoximod conjugate for programmed chemoimmunotherapy
por: Yang, Zhaoxuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dhja8fpkb3kmqlsd1qooirjbks